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Abstract  
AIM: The aim of the present paper was to identify prognostic factors for relapse and mortality in 
patients with hospital-acquired infections caused by Clostridium difficile. 
MATERIAL AND METHODS: This study included 133 patients with healthcare facility-associated 
disease caused by C. difficile. The medical records of all patients with their clinical history and 
laboratory data were analyzed. 
RESULTS: Patients with one onset of disease were 105 (78.9%), 28 (21.1%) experienced a 
relapse and seven (5.2%) patients not survived infection. The average age in our patients was over 
65 years (64.5 years in the survived patients and 78.8 in patient who died, p = 0.01). All of patients 
had received antibiotic treatment (cephalosporins – 83.4%, aminoglycosides – 21.5% and 
penicillins – 20.3%) and 40.6% of patients received acid-reducing therapy. There was no difference 
between patients with one onset of disease/patients with relaps; and survived/died in number of 
administered antibiotics, duration of administration, administration of acid-reducing treatment or 
length of hospital stay (p > 0.05). CRP levels were significantly higher in the group of patients who 
died compared with recovered (p < 0.001).   
CONCLUSION:  C. difficile-associated diarrhea is a common nosocomial disease with high relapse, 
and significant mortality rate particularly in the elderly.   
 
 
 
 
 
Introduction 
Clostridium difficile (C. difficile) is an 
anaerobe, Gram positive, sporogenic bacterium found 
in soil and intestinal tract of humans and animals. It is 
excreted by host through stool and the infection 
develops through activation of spores that are present 
in digestive tract or through fecal-oral pathway, by 
ingestion of spores found on surfaces or hands of 
health care staff in hospital settings [1]. C. difficile 
produces at least two different toxins, toxin A and/or 
toxin B, both of which are cytotoxic and 
enteropathogenic and cause diarrhea and 
enterocolitis [2]. The disease usually develops after 
administration of antibiotics that disturb host's normal 
gut flora [3]. The disease may occur sporadically, but 
in the past few years it became epidemic in hospitals 
and other public health care facilities. With appropriate 
treatment, the disease mostly ends by restitution to 
health; however, recurrence may occur, while in most 
severe cases, death may occur as well [1, 3].   
The aim of this paper was to analyze and 
compare different types of clinical course of C. difficile 
infection, and to try to identify risk factors that might 
influence relapse or mortality. 
 
Methods 
Patients 
This retrospective study included inpatients 
diagnosed with C. difficile-associated diarrhea 
(CDAD) from January 1, 2009 to December 31, 2012. 
In all patients, the disease was identified at different 
departments of General Hospital Subotica, Serbia 
from which all of them were transferred to the 
Infectious Disease Department of the same hospital. 
 The evaluated data include age, gender and 
date of diagnosis. In all patients, the analyzed data 
included onset of complaints, duration of hospital stay, 
number and time of administration of antibiotics, 
treatment with proton pump inhibitors (PPIs) and H2 
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receptors agonists, patient characteristics as risk 
factors (underlying illness-comorbidities, surgical 
procedures, endoscopy), body temperature, number 
and appearance of stools over 24-hour period, white 
blood cells (WBC) count, and C-reactive protein 
(CRP) levels. The above mentioned data were 
obtained from the medical records. In accordance with 
primary objective of this study, patients were classified 
into three groups: (1) those who responded to 
treatment without clinical relapse (2) patients with 
relapse of disease, and (3) patients who died due to 
disease.  
 
Definition 
Healthcare facility-associated disease: (1) the 
presence of diarrhea, defined as passage of 3 or more 
unformed stools in 24 or fewer consecutive hours; (2) 
patients who received antibiotics and in whom 
symptoms occurred at least 48 hours after hospital 
admission, (3) patients with positive laboratory finding 
of C. difficile A toxin and/or B toxin in stool [4].  
 
Testing for C. difficile Toxins 
The presence of C. difficile toxins in stool was 
performed using ELISA-RIDASCREEN Toxin A/B test 
(R-Biopharm AG, Germany). 
 
Statistical Analysis 
Categorical variables are presented as 
absolute and relative frequencies, whereas 
continuous variables are summarized as mean ± SD. 
Chi-square, Z-test and Student's t-test were used for 
comparison of categorical and continuous variables, 
respectively. The rejection of the null hypothesis was 
set at 5% (P < 0.05).  
 
Results 
The study included 133 patients, 67 (50.3%) 
males and 66 (49.6%) females. The average patient 
age was 65.3 years (range: 24.2-89.1 years). In 105 
(78.9%) patients diarrhea did not recur and 28 
(21.1%) patients experienced a relapse. Seven (5.2%) 
patients died (in the group of one-episode C. difficile 
infection five and in the group with relapse two), six of 
seven patients who died due to toxic megacolon 
(85.7%). Details concerning the hospitalization 
treatment, comorbidities, surgical and gastrointestinal 
procedures are presented in Table 1. All of the 
patients were treated with antibiotics. Metronidazole 
as monotherapy was associated with CDAD in one 
patient, while it was given in combination with other 
antibiotics in nine patients. Altogether, 33.1% of the 
patients were treated with more than one antibiotic.  
 
Table 1: Some risk factors in 133 patients with CDAD. 
Treatment and risks for CDAD Number of patients (%) 
Type of antibiotics  
Cephalosporins 111 (83.4) 
Aminoglycosides 28 (21.0) 
Penicillins 27 (20.3) 
Metronidazol 10 (7.5) 
Macrolides 9 (6.7) 
Fluoroquinolones 7 (5.2) 
Other 5 (3.7) 
Number of antibiotics  
1 89 (66.9) 
2 29 (21.8) 
3 10 (7.5) 
4 2 (1.5) 
>4 3 (2.2) 
Acid-reducing treatment 54 (40.6) 
Risk factors  
Post-surgery 37 (27.8) 
Cancer 28 (21.0) 
Diabetes mellitus 22 (16.5) 
Endoscopy 10 (7.5) 
Inflammatory bowel disease 4 (3.0) 
 
Table 2 shows toxins in stool, clinical 
characteristics and presentation in patients with C. 
difficile infection. 
Table 2: Clinical and laboratory findings in 133 patients with 
CDAD. 
 Clinical nad laboratory findings Number of patients (%) 
Symptoms and physical signs  
Mucus in stool 30 (22.5) 
Rectal bleeding 4 (3.0) 
Edema/ascites 27 (20.0) 
Toxic megacolon  9 (6.7) 
Toxins in stool  
Toxin A/B 126 (94.7) 
Toxin A 3 (2.2) 
Toxin B 4 (3.0) 
 
Analysis that evaluated the influence of the 
various risk factors on patients’ on recurrence end 
mortality is shown in Tables 3 and 4. 
Table 3: Clinical and biochemical factors affecting recurrence 
of C. difficile infection. 
  
Initial CDAD (No 
105) 
Recurrent Disease 
(No 28) 
P-
value 
Gender male/female 52/53 15/13 p>0.05 
Years  (± SD) 63.5 ± 14.9 68.4 ± 12.2 p>0.05 
Acid-reducing treatment (%) 45 (42.8) 9 (33.3) p>0.05 
Number of antibiotics (± SD) 1.6 ± 1.0 1.3 ± 0.6 p>0.05 
Duration of treatment  10.9 ± 6.3 11.3 ± 8.0 p>0.05 
Duration of hospital stay  13.4 ± 7.7 12.6 ± 8.5 p>0.05 
CRP (U/L) 80.3 ± 78.8 101.2 ± 91.8 p>0.05 
WBC (x10
9
/L)  13.1 ± 8.2 14.0 ± 6.1 p>0.05 
Number of stools 6.78 ± 4.4 8.5 ± 4.2 p>0.05 
Fever (%) 36 (34.3) 10 (35.7) p>0.05 
CRP - C-reactive protein; WBC - white blood cells 
 
There was no significant difference in clinical 
and biochemical factors between patients with one 
onset of disease and patients who had relapse (p > 
0.05). In contrast to other characteristic, only older 
age of patients (p = 0.01) and increased CRP levels (p 
< 0.001) were associated with high mortality rate. 
 
Discussion 
Because of its mild clinical course without 
complications, CDAD has traditionally been 
considered to be adverse effect of antibiotic therapy 
[5].  In the period 2004-2008, numerous reports from 
USA, Canada and Europe changed perception of 
infection by this anaerobic bacterium that became 
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more aggressive, refractory to standard treatment, 
and with higher numbers of relapses, severe cases 
and higher mortality rates [6-10]. Until now, two 
reports have been published on C. difficile in Serbia: 
Stojanovic and Kocic presented the case of CDAD in 
patient after cholecystectomy, while the other was an 
epidemiological study by the same authors who found 
presence of C. difficile in 4/100 hospitalized patients 
with diarrhea [11, 12]. 
Table 4. Clinical and biochemical factors affecting mortality of 
C. difficile infection 
  Survived (No 126) Died (No 7) P-value 
Gender male/female 65/61 2/5 p>0.05 
Years (±SD) 64.5 ± 14.5 78.8 ± 9.0 p=0.01 
Acid-reducing treatment (%) 51 (40.47) 3 (42.8) p>0.05 
Number of antibiotics (±SD) 1.5 ± 0.9 1.5 ± 0.5 p>0.05 
Duration of treatment  10.9 ± 6.6 10.5 ± 3.6 p>0.05 
Duration of hospital stay  13.2 ± 7.8 10.7 ± 3.6 p>0.05 
CRP (U/L) 85.7 ± 82.0 204.4 ± 11.5 p<0.001 
WBC (x10
9
/L)  13.69 ± 7.8 30.0 ± 30.9 p>0.05 
Number of stools 7.9 ± 4.3 9.8 (5.0) p>0.05 
Fever (%) 43 (34.1) 3 (42.8) p>0.05 
CRP - C-reactive protein; WBC - white blood cells 
 
Although administration of virtually any 
antibiotic may cause development of CDAD, it usually 
occurs after administration of cephalosporins, wide 
spectrum penicillin, clindamycin and fluoroquinolones 
[5, 13]. Metronidazole is rarely associated with this 
disease [14]. Combination of metronidazole and other 
antibiotics was associated with CDAD in 9 patients in 
this study (other antibiotics could have caused this 
multifactor disease in these patients, but 
metronidazole administration did not prevent it), while 
metronidazole alone was the only proven initiator of 
the disease in one patient. 
Although the disease most commonly 
resolves with complete restitution to health, relapses 
occur in 20-25% of patients (even in >30% of cases 
for the new strain), while mortality rates range from 1-
2.5% [15]. The relapse rate among patients in this 
study was similar (21.1%), while mortality rates were 
up to two times higher (5.2%) compared to those 
reported by Zilberberg et al.  (2.3%) [16].   Dallal et al. 
found an increase in rate of fulminant life threatening 
colitis from 0% in 1990 to 3.2% in 2000 [17]. From 
those, 44 patients underwent subtotal or total 
colectomy with high mortality rate of 57%, while 20 
patients died due to colitis. Toxic megacolon was the 
leading cause of death among patients in this study 
(6/7). Several risk or predictive factors for mortality 
have been described, such as old age, elevated WBC, 
prolonged antibiotic use of more than 4 weeks or 
pretreatment with three or more antibiotics [18, 19, 
20]. In the present study only older age and high 
levels of CRP was identified as predisposing factor for 
mortality. 
Previous studies have found numerous risk 
factors for relapse of CDAD, including older age, long 
hospital stays, and concomitant receipt of antacid 
medications, female gender, and additional antibiotics 
for treatment of other infections [21, 22]. Although our 
patients with relapse were on average older than 
those without relapse, there was no significant 
difference between the two groups. Older age was 
identified as predisposing factor only for the most 
severe cases ending with death.  
Although the mechanism of development of 
recurrent C. difficile infection is not entirely 
understood, Maroo and Lamont argued that 
recurrence is more likely to be caused by external re-
infection by C. difficile through feco-oral pathway than 
by reactivation of primary infection [23]. Longer 
hospital stay of patients with CDAD might additionally 
expose patients to spores of C. difficile, thus 
increasing the risk of disease relapse. Among patients 
in this study, the length of hospital stay was not 
identified as risk factor for disease relapse. The group 
of Canadian scientists from Quebec found   that 
recurrences occurred even less commonly in patients 
who were hospitalized for >30 days [24]. Same 
authors concluded that re-infection has minor 
significance and that the main cause of recurrence is 
relapse of the initial disease. Among patients from 
different groups within this study, there was no 
difference in length of antibiotic treatment or number 
of administered antibiotics. It is likely that the main 
factor influencing course of the disease is host's 
immunological response, while antibiotic treatment 
and contamination by spores from hospital 
environment are only prerequisites for development of 
the disease.  
Administration of PPI, i.e. H2 receptors 
agonists, is considered to be predisposing factor for 
both development of the infection and for relapse, 
although opinions of different authors on that matter 
may be conflicting [25, 26]. The United States Food 
and Drug Administration (FDA) have recently informed 
the public on possible association of C. difficile 
infection and administration of PPIs [27]. The 
mechanism of development of the disease has been 
explained by disruption of hydrochloric acid barrier, 
delayed gastric emptying and increased level of bile 
salts [28]. Among patients in this study, acid-reducing 
treatment was not identified as predisposing factor for 
recurrence or death. The group of authors from 
various countries used rigorous selection to perform 
meta analysis of 47 relevant studies and found very 
low quality evidence on association between PPIs and 
C. difficile infection [29]. This opinion has been 
confirmed by the in vitro experiment: it has been 
shown on hospitalized patients, from whom gastric 
aspiration was collected using gastric tube, that 
C. difficile spores were not destroyed by hydrochloric 
acid. Furthermore, no spores germination has been 
shown in gastric contents of patients who received 
PPIs [30].   
This study had several limitations. Firstly, it 
was a retrospective study with relatively small number 
of subjects. Secondly, it did not include all patients, 
because certain number of patients developed 
disease after discharge and were treated at nursing 
homes from which no medical records were later 
available.   
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In conclusion, the CDAD is a significant cause 
of diarrhea syndrome among elderly inpatient 
population, but the number and duration of 
administered antibiotics, length of hospital stay, or 
acid-reducing treatment did not correlate with different 
types of clinical course of C. difficile infection. This 
study confirms that the hospital infection caused by C. 
difficile is present in our settings with significant rates 
of mortality and recurrence. 
 
References 
1. McFarland LV, Stamm WE. Review of Clostridium difficile 
associated diseases. Am J Infect Control. 1986;14(3):99-109. 
2. Savidge TC, Pan WH, Newman P, O'brien M, Anton PM, 
Pothoulakis C. Clostridium difficile toxin B is an inflammatory 
enterotoxin in human intestine. Gastroenterology. 2003;125(2):413-
20. 
3. Barbut F, Petit JC. Epidemiology of Clostridium difficile-
associated infections. Clin Microbiol Infect. 2001;7(8):405−10. 
4. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, 
McDonald LC, et al. Society for Healthcare Epidemiology of 
America; Infectious Diseases Society of America. Clinical practice 
guidelines for Clostridium difficile infection in adults: 2010 update by 
the society for healthcare epidemiology of America (SHEA) and the 
infectious diseases society of America (IDSA). Infect Control Hosp 
Epidemiol. 2010;31(5):431-55.  
5. Blossom DB, McDonald LC. The challenges posed by 
reemerging Clostridium difficile infection. Clin Infect Dis. 
2007;45(2):222-7. 
6. Noren T, Akerlund T, Bäck E, Sjöberg L, Persson I, Alriksson I, et 
al. Molecular epidemiology of hospitalassociated and community-
acquired Clostridium difficile infection in a Swedish county. J Clin 
Microbiol. 2004;42(8):3635–43. 
7. Cramer JP, Burchard GD, Lohse AW. [Old dogmas and new 
perspectives in antibiotic-associated diarrhea] Med Klin (Munich). 
2008;103(5):325-38. 
8 Blanckaert K, Coignard B, Grandbastien B, Astagneau P, Barbut 
F. Update on Clostridium difficile infections. Rev Med Interne. 
2008;29(3):209-14. 
9. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-
associated disease in North America and Europe. Clin Microbiol 
Infect. 2006;12(Suppl 6):2-18. 
10. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud 
S, et al. A predominantly clonal multi-institutional outbreak of 
Clostridium difficile-associated diarrhea with high morbidity 
mortality. N Engl J Med. 2005;353(23):2442-9. 
11. Stojanovic P, Kocic B. Diarrhoea caused by Clostridium difficile 
in patients with postoperative subhepatic abscess. Vojnosanit Pregl. 
2008;65(3):249-54.   
12. Kocic B, Stojanovic P. Clinical importance of Clostridium difficile 
finding in hospitalized patients. Med Pregl. 2008;61(11-12):632-7. 
13. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. 
N Engl J Med. 1994;330 (4):257-62.   
14. Bignardi GE. Risk factors for Clostridium difficile infection. J 
Hospital Infect. 1998; 40(1):1-15. 
15. Bartlett  JG.  Clinical practice. Antibiotic-associated diarrhea.  N 
Engl J Med.  2002; 346(5):334–9. 
16. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult 
Clostridium difficile-related hospitalizations and casefatality rate, 
United States, 2000-2005. Emerg Infect Dis. 2008; 14(6):929-31. 
17. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, 
Lee KK, et al. Fulminant Clostridium difficile: an underappreciated 
and increasing cause of death and complications. Ann Surg. 
2002;235(3):363–72. 
18. Walker KJ, Gilliland SS, Vance-Bryan K, Moody JA, Larsson AJ, 
Rotschafer JC, Guay DR. Clostridium difficile colonization in 
residents of long-term care facilities: prevalence and risk factors. J 
Am Geriatr Soc. 1993;41(9):940–6. 
19. Dharmarajan T, Sipalay M, Shyamsundar R, Norkus E, 
Pitchumoni C. Co-morbidity, not age predicts adverse outcome in 
Clostridium difficile colitis. World J Gastroenterol. 2000;6(2):198–
201. 
20. Lesna M, Parham DM. Risk of diarrhoea due to Clostridium 
difficile during cefotaxime treatment. Mortality due to C. difficile 
colitis in elderly people has been underestimated. BMJ. 
1996;312(7033):778. 
21. Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, 
Konikoff F. Risk factors for severity and relapse of 
pseudomembranous colitis in an elderly population. Colorectal Dis. 
2007;9(2):173-7. 
22. Barbut F, Richard A, Hamadi K et al. Epidemiology of 
recurrences or reinfections of Clostridium difficile-associated 
diarrhea. J Clin Microbiol. 2000;38(6):2386–8. 
23. Maroo S, Lamont JT. Recurrent clostridium difficile. 
Gastroenterology. 2006;130(4): 1311-6. 
24. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et 
al. Increasing risk of relapse after treatment of clostridium difficile 
colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591-7. 
25. Johnson S. Recurrent Clostridium difficile infection: a review of 
risk factors, treatments, and outcomes. Journal of Infection. 
2009;58(6):403-10. 
26. Hookman P, Barkin J. Clostridium difficile associated infection, 
diarrhea and colitis.   World J Gastroenterol. 2009;15(13):1554-80. 
27. Elixhauser A, Jhung M. Clostridium Difficile-Associated Disease 
in U.S. Hospitals, 1993–2005. HCUP Statistical Brief #50 April 
2008. Agency for Healthcare Research and Quality, Rockville MD. 
Available at: http://www.hcup-
us.ahrq.gov/reports/statbriefs/sb50.pdf. 
28. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile 
survives in room air on moist surfaces and in gastric contents with 
reduced acidity: a potential mechanism to explain the association 
between proton pump inhibitors and C. difficile-associated 
diarrhea? Antimicrob Agents Chemother. 2007;51(8):2883–7. 
29. Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, 
AlGhamdi M, et al. Association between proton pump inhibitor 
therapy and clostridium difficile infection: a contemporary 
systematic review and meta-analysis. PLoS One. 
2012;7(12):e50836. 
30. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential 
mechanisms to explain the association between proton pump 
inhibitors and Clostridium difficile infection. Antimicrob Agents 
Chemother. 2009;53(10):4133–7. 
